Balance Sheet Insights: Dynavax Technologies Corp. (DVAX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.

In the latest session, Dynavax Technologies Corp. (NASDAQ: DVAX) closed at $11.01 down -5.49% from its previous closing price of $11.65. In other words, the price has decreased by -$5.49 from its previous closing price. On the day, 4.56 million shares were traded. DVAX stock price reached its highest trading level at $11.16 during the session, while it also had its lowest trading level at $10.48.


For a deeper understanding of Dynavax Technologies Corp.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.99 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 27.29. For the most recent quarter (mrq), Quick Ratio is recorded 14.10 and its Current Ratio is at 15.20. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.41.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on February 01, 2024, initiated with a Neutral rating and assigned the stock a target price of $20.

On September 27, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $22.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 01 ’24 when Burgess Justin sold 20,526 shares for $12.78 per share. The transaction valued at 262,322 led to the insider holds 0 shares of the business.

Janssen Robert sold 1,500 shares of DVAX for $22,500 on Jan 04 ’24. The SVP and CMO now owns 49,925 shares after completing the transaction at $15.00 per share. On Jan 02 ’24, another insider, Novack David F, who serves as the President & COO of the company, sold 9,000 shares for $14.45 each. As a result, the insider received 130,050 and left with 3,187 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DVAX now has a Market Capitalization of 1524554752 and an Enterprise Value of 1105374976. As of this moment, Dynavax’s Price-to-Earnings (P/E) ratio for their current fiscal year is 203.89, and their Forward P/E ratio for the next fiscal year is 26.59. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.09 while its Price-to-Book (P/B) ratio in mrq is 2.33. Its current Enterprise Value per Revenue stands at 4.681 whereas that against EBITDA is -65.963.

Stock Price History:

Over the past 52 weeks, DVAX has reached a high of $15.15, while it has fallen to a 52-week low of $10.60. The 50-Day Moving Average of the stock is -8.75%, while the 200-Day Moving Average is calculated to be -17.87%.

Shares Statistics:

For the past three months, DVAX has traded an average of 1.99M shares per day and 1868800 over the past ten days. A total of 130.62M shares are outstanding, with a floating share count of 130.16M. Insiders hold about 0.35% of the company’s shares, while institutions hold 96.57% stake in the company. Shares short for DVAX as of 1713139200 were 18536992 with a Short Ratio of 9.33, compared to 1710460800 on 17348223. Therefore, it implies a Short% of Shares Outstanding of 18536992 and a Short% of Float of 17.31.

Most Popular

[the_ad id="945"]